A002720 Stock Overview
Engages in manufacturing, importing, exporting, selling, and distributing pharmaceutical products. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Kukje Pharma Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩4,850.00 |
| 52 Week High | ₩8,120.00 |
| 52 Week Low | ₩4,365.00 |
| Beta | 0.61 |
| 1 Month Change | -16.09% |
| 3 Month Change | -10.52% |
| 1 Year Change | -23.26% |
| 3 Year Change | -7.97% |
| 5 Year Change | 24.35% |
| Change since IPO | 230.09% |
Recent News & Updates
Kukje Pharma's (KRX:002720) Strong Earnings Are Of Good Quality
Nov 21
Kukje Pharma Co., Ltd.'s (KRX:002720) 28% Price Boost Is Out Of Tune With Revenues
Aug 08What Kukje Pharma Co., Ltd.'s (KRX:002720) 27% Share Price Gain Is Not Telling You
Jun 24Recent updates
Kukje Pharma's (KRX:002720) Strong Earnings Are Of Good Quality
Nov 21Kukje Pharma Co., Ltd.'s (KRX:002720) 28% Price Boost Is Out Of Tune With Revenues
Aug 08What Kukje Pharma Co., Ltd.'s (KRX:002720) 27% Share Price Gain Is Not Telling You
Jun 24Kukje Pharma Co., Ltd.'s (KRX:002720) Share Price Not Quite Adding Up
Mar 20Kukje Pharma's (KRX:002720) Solid Profits Have Weak Fundamentals
Mar 20If You Had Bought Kukje Pharma (KRX:002720) Stock A Year Ago, You Could Pocket A 121% Gain Today
Mar 19These 4 Measures Indicate That Kukje Pharma (KRX:002720) Is Using Debt Reasonably Well
Feb 21What Type Of Shareholders Own The Most Number of Kukje Pharma Co., Ltd. (KRX:002720) Shares?
Jan 25
Kukje Pharma Co., Ltd.'s (KRX:002720) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Dec 30Investors Who Bought Kukje Pharma (KRX:002720) Shares Five Years Ago Are Now Up 227%
Dec 04Shareholder Returns
| A002720 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | -2.3% | -1.7% | -3.7% |
| 1Y | -23.3% | 0.1% | -10.4% |
Return vs Industry: A002720 underperformed the KR Pharmaceuticals industry which returned 3.2% over the past year.
Return vs Market: A002720 underperformed the KR Market which returned -9.1% over the past year.
Price Volatility
| A002720 volatility | |
|---|---|
| A002720 Average Weekly Movement | 6.6% |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in KR Market | 12.7% |
| 10% least volatile stocks in KR Market | 3.3% |
Stable Share Price: A002720 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A002720's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1959 | 244 | Tae-hoon Nam | www.kukjepharm.co.kr |
Kukje Pharma Co., Ltd. engages in manufacturing, importing, exporting, selling, and distributing pharmaceutical products. The company offers pharmaceutical products, including ETC and OTC products, raw materials, intermediates, and side chain products, as well as cosmetics and health care products. Its products include cephalosporins, quinolones, tetracycline, aminoglycosides, macrolides, other antibiotics, ophthalmic, antifungal and antiviral agents, ophthalmic agents, adrenal corticosteroids, CNS and osteoporotic agents, antihistamines, NSAIDS and other analgesics, gastrointestinal and cardiovascular agents, antidiabetics, genitourinary and respiratory agents, other ETC products, and other products.
Kukje Pharma Co., Ltd. Fundamentals Summary
| A002720 fundamental statistics | |
|---|---|
| Market cap | ₩98.76b |
| Earnings (TTM) | ₩4.11b |
| Revenue (TTM) | ₩150.12b |
24.0x
P/E Ratio0.7x
P/S RatioIs A002720 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A002720 income statement (TTM) | |
|---|---|
| Revenue | ₩150.12b |
| Cost of Revenue | ₩72.07b |
| Gross Profit | ₩78.05b |
| Other Expenses | ₩73.95b |
| Earnings | ₩4.11b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 201.76 |
| Gross Margin | 51.99% |
| Net Profit Margin | 2.74% |
| Debt/Equity Ratio | 32.3% |
How did A002720 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 09:49 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Kukje Pharma Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|